SciClone to Report Fourth Quarter 2004 Results on February 23, 2005

    Business Editors

    SAN MATEO, Calif.--(BUSINESS WIRE)--Jan. 31, 2005--SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) today announced that it plans to report fourth quarter and full year 2004 results and host a conference call on February 23, 2005.
    The conference call will contain forward-looking statements. Financial and statistical information to be discussed on the call will be posted on the Investor Relations section of SciClone's web site at www.sciclone.com prior to the commencement of the conference call.

DATE: Wednesday, February 23, 2005

TIME: 11:30 a.m. EST (8:30 a.m. PST)

WEBCAST: live call and replay accessible at www.sciclone.com

LIVE CALL: 800-706-7748 (U.S./Canada) 617-614-3473 (international) passcode: 23687658

REPLAY: 888-286-8010 (U.S./Canada) 617-801-6888 (international) passcode: 56492916

    About SciClone

    SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN is currently being evaluated in two phase 3 hepatitis C clinical trials in the United States. ZADAXIN is also being evaluated in other late-stage clinical trials for the treatment of hepatitis B and certain cancers. The company's other principal drug development candidate is SCV-07, which is currently being evaluated in pre-clinical studies for the treatment of viral and other infectious disease. For more information about SciClone, visit www.sciclone.com.

--30--YM/cg*

CONTACT: SciClone Pharmaceuticals, Inc. Richard A. Waldron, 650-358-3437

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY EARNINGS CONFERENCE CALLS SOURCE: SciClone Pharmaceuticals, Inc.

Copyright Business Wire 2005